CTNM files 8-K on Phase 2 PIPE-307 VISTA MS topline results

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. (CTNM) reported that it issued a press release with topline data from its Phase 2 PIPE-307 VISTA trial for treating relapsing-remitting multiple sclerosis. The company furnished this press release as Exhibit 99.1 to the report and incorporated it by reference, indicating that detailed clinical results are contained in that exhibit.

Insights

Biotech and clinical-trial analyst

CTNM discloses that Phase 2 MS trial topline data are now available via press release.

Contineum Therapeutics announced that topline data from its Phase 2 PIPE-307 VISTA trial in relapsing-remitting multiple sclerosis are now summarized in a press release furnished as Exhibit 99.1. Topline data typically cover primary endpoints and key safety findings without full detail.

Because the text only states that topline data were reported, without describing the results, no directional conclusion about efficacy or safety can be drawn from this excerpt alone. The clinical and financial relevance depends on the specific outcomes, which are contained in the referenced press release.

Subsequent communications and future company filings may elaborate on the Phase 2 results and any implications for the development path of PIPE-307 in multiple sclerosis.

false 0001855175 0001855175 2025-11-20 2025-11-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 20, 2025

Contineum Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42001		27-1467257
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3565 General Atomics Court, Suite 200 San Diego, California		92121
(Address of principal executive offices)		(Zip Code)

(858) 333-5280

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.001 per share		CTNM		The Nasdaq Global Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company          ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 8.01 Other Events.

On November 20, 2025, Contineum Therapeutics, Inc. issued a press release in which it reported topline data from its Phase 2 PIPE-307 VISTA trial for the treatment of relapsing-remitting multiple sclerosis. 

A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)  Exhibits.

Exhibit No.		Description
99.1		Press release dated November 20, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 20, 2025

Contineum Therapeutics, Inc.
By:		/s/ Peter Slover
		Peter Slover
		Chief Financial Officer Principal Financial Officer and Principal Accounting Officer

FAQ

What did Contineum Therapeutics (CTNM) announce in this 8-K filing?

Contineum Therapeutics reported that it issued a press release with topline data from its Phase 2 PIPE-307 VISTA trial for relapsing-remitting multiple sclerosis and furnished that press release as Exhibit 99.1.

Which clinical trial is mentioned for Contineum Therapeutics (CTNM)?

The report mentions the Phase 2 PIPE-307 VISTA trial, which evaluates PIPE-307 for the treatment of relapsing-remitting multiple sclerosis.

Where can investors find the detailed Phase 2 data for CTNM's PIPE-307 VISTA trial?

Detailed information is provided in the press release that Contineum furnished as Exhibit 99.1, which is incorporated by reference into the report.

What is the main purpose of this Contineum Therapeutics (CTNM) 8-K?

The main purpose is to formally note that Contineum issued a press release reporting topline data from its Phase 2 PIPE-307 VISTA multiple sclerosis trial and to attach that press release as an exhibit.

Does this CTNM filing include financial statements or only other events?

The report is categorized under Item 8.01 Other Events and highlights the press release with Phase 2 topline data; it lists exhibits under Item 9.01 rather than providing new financial statements.

Which exhibit in the CTNM 8-K contains the PIPE-307 trial press release?

The press release dated November 20, 2025, that describes topline data from the Phase 2 PIPE-307 VISTA trial is furnished as Exhibit 99.1.